VR Logo

SAB Biotherapeutics Inc. (SABS) download report


Healthcare | Biotechnology & Pharma Research

SAB Biotherapeutics Inc. (SABS) Premium Coverage

52 Stocks to buy right now

Join Value Research Stock Advisor now and be among the first to discover Stock Ideas

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

About The Company

Business: SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies based on human antibodies.

IPO Date: 09-Feb-2021

Exec. Chairman: Mr. Samuel J. Reich

Co-Founder, Pres, CEO & Director: Dr. Eddie Joe Sullivan Ph.D.

Listing: NASDAQ: SABS

Country: United States

Headquarters: Sioux Falls, SD

Website: https://www.sabbiotherapeutics.com

Key Facts

Market cap: $60.61 Mln

Revenue (TTM): $72.68 Mln

Earnings (TTM): $-11.66 Mln

Cash: $22.41 Mln

Total Debt: $6.41 Mln

Insider's Holding: 38.08%

Liquidity: Low

52 Week range: $1.11 - 12.90

Shares outstanding: 42,987,600

Stock Performance

Time Period SAB Biotherapeutics (SABS) S&P BSE Sensex* S&P Small-Cap 600*
YTD-82.20-8.47-19.22
1 month-29.80-2.85-9.34
3 months-33.81-7.98-14.58
1 Year-86.021.46-17.64
3 Years--10.625.91
5 Years--11.565.64
10 Years--11.8310.10
As on 29-Jun-2022 *As on 30-Jun-2022